NPM1 and acute myeloid leukemia: Similarly, the Phase 1b study of bleximenib combined with the 7+3 regimen targeted ND AML, achieving an overall response rate (ORR) of 93% and CR/CRh in 79% of patients, with NPM1-mutated cases showing slightly better outcomes than KMT2Ar cases [29].